Defence Therapeutics (TSE:DTC) has released an update.
Defence Therapeutics has announced receiving a No Objection Letter from Health Canada for a Phase I clinical trial of its anti-cancer molecule, ACCUM-002, aimed at treating melanoma. The trial will assess the safety, tolerability, and preliminary efficacy of the molecule, both as a standalone treatment and in combination with Opdualag, a known immunotherapy. With the global cancer immunotherapy market expected to grow significantly, Defence is positioning itself as a potential leader in innovative cancer treatments.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
